1. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: Efficacy and outcomes
- Author
-
Masaaki Watanabe, Shigehiro Kokubu, Wasaburo Koizumi, Shouko Komori, Kazushige Hayakawa, Tsutomu Minamino, Hajime Yamamoto, Juichi Takada, Yusuke Okuwaki, Yoshiaki Tanaka, Hisashi Hidaka, Akitaka Shibuya, and Takahide Nakazawa
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,business.industry ,Proportional hazards model ,medicine.medical_treatment ,Gastroenterology ,medicine.disease ,Thrombosis ,Radiation therapy ,medicine.anatomical_structure ,Hepatocellular carcinoma ,Internal medicine ,Total dose ,medicine ,In patient ,business ,Adverse effect ,Vein - Abstract
Background and Aim To examine the efficacy and outcomes of radiotherapy (RT) in patients who have hepatocellular carcinoma with invasion to intrahepatic large vessels (IHLVs). Methods Sixty-seven patients who had advanced hepatocellular carcinoma with invasion to IHLVs received three-dimensional conformal RT. IHLV invasion was associated with portal venous tumor thrombosis in 40 patients, tumor thrombosis involving the hepatic vein in 17, and both findings in 10. A daily radiation dose of 1.8–2 Gy was administered using 6 or 10 MV X-rays to deliver a total dose of 30–56 Gy. Results The overall objective response rate (complete response plus partial response) was 45% (n = 30). The median survival time was 13.7 months in the responder group and 5.9 months in the nonresponder group. An objective response was observed in 28 (56%) of 50 patients with Child-Pugh (C-P) class A and in 2 (12%) of 17 patients with C-P class B. Hepatic function of C-P class A was an independent factor for both RT responder and overall survival on Cox regression analysis (hazard ratio = 9.5, 95% confidence interval = 1.97–46.2, P = 0.005; and hazard ratio = 0.39, 95% confidence interval = 0.2–0.77, P = 0.007, respectively). Conclusion RT is an effective treatment option without serious adverse events. RT should be considered for the patients with better hepatic function who have invasion to IHLVs.
- Published
- 2014